GENEURO SA (GNRO.PA) Stock Price, Forecast & Analysis
Europe - EPA:GNRO - CH0308403085 - Common Stock
GNRO.PA Key Statistics, Chart & Performance
The current stock price of GNRO.PA is 0.0354 EUR. In the past month the price decreased by -11.5%. In the past year, price decreased by -45.54%.
GNRO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.51 | 48.29B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.32B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 23.91 | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 894.88M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 509.78M | ||
| FYB.DE | FORMYCON AG | N/A | 405.97M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
Related stock screener links
About GNRO.PA
Company Profile
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Company Info
GENEURO SA
3, Chemin du Pre-Fleuri
Plan-les-Ouates GENEVE CH
Employees: 17
Phone: 41225524800
GENEURO SA / GNRO.PA FAQ
What does GNRO do?
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Can you provide the latest stock price for GENEURO SA?
The current stock price of GNRO.PA is 0.0354 EUR. The price decreased by -7.33% in the last trading session.
Does GENEURO SA pay dividends?
GNRO.PA does not pay a dividend.
What is the ChartMill rating of GENEURO SA stock?
GNRO.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is GNRO.PA stock listed?
GNRO.PA stock is listed on the Euronext Paris - Matif exchange.
GNRO.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GNRO.PA. When comparing the yearly performance of all stocks, GNRO.PA is a bad performer in the overall market: 93.28% of all stocks are doing better.
GNRO.PA Financial Highlights
Over the last trailing twelve months GNRO.PA reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -17.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -231.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GNRO.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of -28.12% and a revenue growth -100% for GNRO.PA